A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers

Annals of Oncology

Volumn 21, Issue 10, 2010, Pages 1999-2004

  El Rayes, B F ^a   Zalupski, M ^b   Bekai Saab, T ^c   Heilbrun, L K ^d   Hammad, N ^a   Patel, B ^a   Urba, S ^b   Shields, A F ^a   Vaishampayan, U ^a   Dawson, S ^a   Almhanna, K ^a   Smith, D ^d   Philip, P A ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

Author keywords

Bevacizumab; Docetaxel; Gastric cancer; Oxaliplatin

Indexed keywords

BEVACIZUMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ACUTE DISEASE; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTERY THROMBOSIS; ARTICLE; BONE METASTASIS; CANCER SURVIVAL; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG RESPONSE; DRUG TOLERABILITY; ESOPHAGUS FISTULA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; INFECTION; LEUKOPENIA; LIVER METASTASIS; LIVER TOXICITY; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; PERITONEUM METASTASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; SIDE EFFECT; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMATITIS; SURVIVAL TIME; TUMOR LOCALIZATION; VENOUS THROMBOEMBOLISM; VOMITING; WOUND DEHISCENCE;

EID: 77957160694     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq065     Document Type: Article

References (29)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; (55): 2): 74-108.
2. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24(14): 2137-2150.
3. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265(10): 1287-1289.
4. Van Cutsem E, Moiseyenko VM, Tjulandin S et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24(31): 4991-4997.
5. Cunningham D, Starling N, Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358(1): 36-46.
6. Webb A, Cunningham D, Scarffe JH et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15(1): 261-267.
7. Kim KH, Park YS, Chang MH et al. A phase I/II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer. Cancer Chemother Pharmacol 2009; 64(2): 347-353.
8. Hejna M, Raderer M, Zacherl J et al. Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease: results of the Central European Cooperative Oncology Group Study ESGAS.1.2.001. Anticancer Drugs 2008; 19(5): 535-539.
9. Kim JG, Sohn SK, Chae YS et al. Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group. Br J Cancer 2008; 98(3): 542-546.
10. Richards D, McCollum D, Wilfong L et al. Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction. Ann Oncol 2008; 19(1): 104-108.
11. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6(4): 273-286.
12. Folkman J. Endothelial cells and angiogenic growth factors in cancer growth and metastasis. Introduction. Cancer Metastasis Rev 1990; 9(3): 171-174.
13. Yamamoto S, Yasui W, Kitadai Y et al. Expression of vascular endothelial growth factor in human gastric carcinomas. Pathol Int 1998; 48(7): 499-506.
14. Takahashi Y, Cleary KR, Mai M et al. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin Cancer Res 1996; 2(10): 1679-1684.
15. Ikeguchi M, Oka S, Saito H et al. The expression of vascular endothelial growth factor and proliferative activity of cancer cells in gastric cancer. Langenbecks Arch Surg 1999; 384(3): 264-270.
16. Kanai T, Konno H, Tanaka T et al. Anti-tumor and anti-metastatic effects of human-vascular-endothelial-growth-factor-neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice. Int J Cancer 1998; 77(6): 933-936.
17. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350(23): 2335-2342.
18. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357(26): 2666-2676.
19. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355(24): 2542-2550.
20. Shah MA, Ramanathan RK, Ilson DH et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006; 24(33): 5201-5206.
21. Kelsen DP, Jhawer D, Ilson DH et al. Analysis of survival with modified docetaxel, cisplatin, fluorouracil and bevacizumab in patients with metastatic gastric and GEJ adenocarcinoma: results of a phase II trial. 2009 ASCO Annual Meeting, Orlando, FL. J Clin Oncol 2009; 27:15s (Abstr 4512).
22. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92(3): 205-216.
23. National Cancer Institute. National Cancer Institute Common Toxicity Criteria Version 3 http://ctep.cancer.gov/reporting/ctc.html (date last accessed, 28 February 2010).
24. Lee E, Wang JW. Statistical Methods for Survival Data Analysis, 3rd edition. Hoboken, NJ: Wiley 2003.
25. Enzinger PC, Ryan DP, Regan EM et al. Phase II trial of docetaxel cisplatin irinotecan and bevacizumab in metastatic esophagogastric cancer. 2008 ASCO Annual Meeting, Chicago, IL. J Clin Oncol 2008; 26 (Suppl): (Abstr 4552).
26. Asmis TR, Capanu M, Kelsen DP, Shah MA. Systemic chemotherapy does not increase the risk of gastrointestinal perforation. Ann Oncol 2007; 18(12): 2006-2008.
27. Grothey A, Sugrue MM, Purdie DM et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008; 26(33): 5326-5334.
28. Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 2009; 10(6): 559-568.
29. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25(12): 1539-1544.